Windlas Biotech proposes to buy back 4,70,000 equity shares (2.23% of capital) at ₹1,000 per share via tender offer, aggregating ₹47 crore.
The buyback offers a 31-33% premium to historical VWAPs and reserves 97,342 shares for small shareholders holding ≤232 shares.
Promoters have declared non-participation, and the offer opens on April 30, 2026, closing on May 7, 2026, with settlement by May 25, 2026.
Funding will utilize free reserves, with post-buyback debt-equity ratio remaining at 0.06x, and EPS expected to improve from ₹29.19 to ₹29.86.